IRIS
DANESE, Silvio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 20.374
EU - Europa 3.655
AS - Asia 735
AF - Africa 606
Continente sconosciuto - Info sul continente non disponibili 44
SA - Sud America 42
OC - Oceania 39
Totale 25.495
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 20.199
FI - Finlandia 1.006
IE - Irlanda 703
NG - Nigeria 592
FR - Francia 402
CN - Cina 382
DE - Germania 370
NL - Olanda 221
GB - Regno Unito 199
IT - Italia 190
SE - Svezia 185
CA - Canada 163
TR - Turchia 99
BE - Belgio 80
IL - Israele 69
RU - Federazione Russa 61
IN - India 57
RO - Romania 46
A2 - ???statistics.table.value.countryCode.A2??? 41
CL - Cile 35
ES - Italia 34
AU - Australia 33
PL - Polonia 33
SG - Singapore 30
JP - Giappone 27
UA - Ucraina 26
GR - Grecia 23
IR - Iran 23
NO - Norvegia 16
AT - Austria 15
BD - Bangladesh 11
CH - Svizzera 9
MD - Moldavia 9
EG - Egitto 8
HK - Hong Kong 8
MX - Messico 8
DK - Danimarca 7
NZ - Nuova Zelanda 6
AE - Emirati Arabi Uniti 5
BR - Brasile 4
IQ - Iraq 4
SA - Arabia Saudita 4
CZ - Repubblica Ceca 3
EU - Europa 3
GT - Guatemala 3
HU - Ungheria 3
MO - Macao, regione amministrativa speciale della Cina 3
MY - Malesia 3
PT - Portogallo 3
AL - Albania 2
KR - Corea 2
MK - Macedonia 2
TN - Tunisia 2
AR - Argentina 1
BG - Bulgaria 1
BY - Bielorussia 1
CO - Colombia 1
CY - Cipro 1
EE - Estonia 1
ET - Etiopia 1
ID - Indonesia 1
KE - Kenya 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LI - Liechtenstein 1
MT - Malta 1
NP - Nepal 1
PA - Panama 1
PH - Filippine 1
PK - Pakistan 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
UG - Uganda 1
VE - Venezuela 1
ZA - Sudafrica 1
Totale 25.495
Salva come PNG Salva come JPEG
Città #
Chandler 4.195
Wilmington 4.032
San Mateo 1.633
Ann Arbor 1.257
Helsinki 1.006
Lawrence 712
Princeton 712
Leawood 703
Dublin 700
Boardman 646
Benin City 589
Ashburn 492
Paris 388
New York 387
Woodbridge 378
Fairfield 364
Shanghai 338
Amsterdam 211
London 153
Toronto 137
Seattle 117
Norwalk 103
San Diego 93
Kocaeli 92
Phoenix 78
Brussels 74
Milan 63
Redwood City 46
Monmouth Junction 36
Los Angeles 35
Falls Church 34
Abbiategrasso 33
Clearwater 33
Pune 33
Cambridge 29
Houston 25
Moscow 25
Des Moines 24
Redmond 21
Falkenstein 19
Singapore 17
Tappahannock 17
Las Vegas 13
Beijing 11
Gunzenhausen 11
Raleigh 11
Warsaw 11
Andover 9
Chisinau 9
Duncan 9
Hanover 9
La Canada Flintridge 9
Novokuznetsk 9
St Louis 9
Vienna 9
Dallas 8
Kemerovo 8
Cairo 7
Sacramento 7
Zhengzhou 7
Cupertino 6
Henderson 6
Reghin 6
Tokyo 6
Valencia 6
Buffalo 5
Leipzig 5
Ottawa 5
Pitesti 5
Saint Louis 5
Washington 5
Winnipeg 5
Apo 4
Athens 4
Auckland 4
Genoa 4
Glasgow 4
Istanbul 4
Köln 4
Madrid 4
Melbourne 4
Mumbai 4
Saint Paul 4
San Pedro 4
Santa Clara 4
Sydney 4
Vancouver 4
Adliswil 3
Alexandria 3
Augusta 3
Berlin 3
Collegeville 3
Columbus 3
Groningen 3
Guatemala City 3
Hangzhou 3
Harrisburg 3
Hyderabad 3
La Neuveville 3
Leninsk-kuznetskiy 3
Totale 20.410
Salva come PNG Salva come JPEG
Nome #
Biological agents for ulcerative colitis : Hypes and hopes 251
Vascular endothelial growth factor C disrupts the endothelial lymphatic barrier to promote colorectal cancer invasion 175
Multimodal treatment of perianal fistulas in Crohn's disease: seton versus anti-TNF versus advancement plasty (PISA): study protocol for a randomized controlled trial 152
Role of bowel ultrasound as a predictor of surgical recurrence of Crohn's disease 82
A multicentre prospective cohort study assessing the effectiveness of budesonide MMX (R) (Cortiment (R)(MMX (R))) for active, mild-to-moderate ulcerative colitis 71
Darvadstrocel for the treatment of patients with perianal fistulas in Crohn's disease 68
Helicobacter pylori eradication down-regulates matrix metalloproteinase-9 expression in chronic gastritis and gastric ulcer 67
Adalimumab in ulcerative colitis: Ready for prime time 67
Laparoscopic Surgery for Recurrent Crohn's Disease 66
Activation of the VEGFC/VEGFR3 Pathway Induces Tumor Immune Escape in Colorectal Cancer 66
Ulcerative Colitis and Crohn's Disease Have Similar Burden and Goals for Treatment 65
Bacterial sensor triggering receptor expressed on myeloid cells-2 regulates the mucosal inflammatory response 64
New Drug Delivery Systems in Inflammatory Bowel Disease: MMX (TM) and Tailored Delivery to the Gut 64
Thrombomodulin-activated protein C-endothelial protein C receptor pathway: A novel anti-inflammatory system in IBD 62
Crohn's disease 62
Helicobacter pylori CagA-positive strains affect oxygen free radicals generation by gastric mucosa 61
Galectin-2 induces apoptosis of lamina propria T lymphocytes and ameliorates acute and chronic experimental colitis in mice 61
Evolving strategies and goals of treatment in ulcerative colitis 61
IBD Of mice and men-shedding new light on IL-13 activity in IBD 60
A Prospective Comparison Between Computerized Tomography (CT) and Magnetic Resonance (MR) in Ileo-Colonic Crohn's Disease: A Single-Center Experience. 60
Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease 60
A NEW TOOL FOR PRE-COLONOSCOPY DYING OF THE COLONIC MUCOSA WITH ORAL MULTI MATRIX RELEASE TECHNOLOGY (MMX (R))-RELEASED METHYLENE BLUE: A PRELIMINARY STUDY 59
Risk factors for complications after ileocolonic resection for Crohn's disease with a major focus on the impact of preoperative immunosuppressive and biologic therapy: A retrospective international multicentre study. 59
Unique role of junctional adhesion molecule-A in maintaining mucosal homeostasis in inflammatory bowel disease 58
Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis 58
A liophylized and inactivated colture of Lactobacillus acidophilus increases Helicobacter pylori eradication rate 58
Association between Helicobacter pylori CagA-positive strains and ischemic stroke. 57
Colitis-associated cancer: the dark side of inflammatory bowel disease 57
Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients 56
Complementary and alternative medicine in inflammatory bowel diseases: what is the future in the field of herbal medicine? 56
ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer 56
Methotrexate for Corticosteroid- Dependent Ulcerative Colitis: Results of a Placebo Randomized Controlled Trial 56
The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes 55
Dysregulated intracellular redox equilibrium in intestinal lamina propria T cells (LPT) contributes to mucosal inflammation 55
Impact of Tumour Necrosis Factor Antagonists on Avoiding Surgery in Stricturing Crohn's Disease: A Tertiary Center Real-Life Experience 55
Ulcerative Colitis 55
Meta-Analysis of the Association Between Anti-Tumour Necrosis Factor Use and Lymphoma Risk in Patients With Inflammatory Bowel Disease: Methodological Considerations 54
Second-Generation Corticosteroids for the Treatment of Crohn's Disease and Ulcerative Colitis: More Effective and Less Side Effects? 54
Review article: causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-alpha therapy 54
JAK inhibitors: Novel developments in management of ulcerative colitis 54
Effect of Tumor Necrosis Factor-alpha Blockade on Mucosal Addressin Cell-adhesion Molecule-1 in Crohn's Disease 54
Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis 54
Budesonide : teaching an old dog new tricks for inflammatory bowel disease treatment 53
Emerging biologics in the treatment of inflammatory bowel disease : what is around the corner? 53
Adalimumab is effective in achieving clinical and endoscopic long-term deep remission : a case report 53
Regulatory T-Cell Therapy for Crohn's Disease: In Vivo Veritas 53
Balanced propofol sedation administered by nonanesthesiologists : the first Italian experience 53
Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease 53
Correlation between delta(CO2)-C-13 excretion and prevalence of dyspeptic symptoms in subjects evaluated for H. pylori infection by C-13-urea breath test 53
Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients 53
WallFlex colonic stent placement for management of malignant colonic obstruction : a prospective study at two centers 53
Adalimumab in active ulcerative colitis: A "real-life" observational study 53
Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study 53
All That Glitters is Not Gold in Vedolizumab Therapy for Patients With Inflammatory Bowel Diseases and Primary Sclerosing Cholangitis 53
Narrow-band imaging endoscopy to assess mucosal angiogenesis in inflammatory bowel disease: a pilot study 53
A Surface Plasmon Resonance-based assay to measure serum concentrations of therapeutic antibodies and anti-drug antibodies 52
JAK selectivity for inflammatory bowel disease treatment: does it clinically matter? 52
Editorial: to facitinib and biologics for moderate-to-severe ulcerative colitis-what is best in class? Authors' reply 52
Ustekinumab in the management of Crohn's disease: Expert opinion 52
Helicobacter pylori infection in rheumatoid arthritis - Reply 52
Intravenous Versus Oral Iron for the Treatment of Anemia in Inflammatory Bowel Disease A Systematic Review and Meta-Analysis of Randomized Controlled Trials 52
Effect of Oral Administration of Methylene Blue MMx (R) Tablets on Double-Stranded DNA Damage Assessed by gamma H2AX Analysis of Colon Biopsy Samples - A Single Center, Open Label, Safety, Phase II Study 52
Association between Helicobacter pylori cytotoxic type I strains and migraine with aura 52
Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials 52
The bacterial sensor Triggering Receptor Expressed on Myeloid cells 2 (TREM-2) is a crucial pathogenic mediator in inflammatory bowel disease (IBD) 52
Colifagina, a novel preparation of 8 lysed bacteria ameliorates experimental colitis 52
Heat shock protein 47 is a new candidate molecule as anti-fibrotic treatment of Crohn's disease: authors' reply 51
Anemia in Inflammatory Bowel Disease: The Opening of Pandora's Box? 51
Surgical rates in the era of biological therapy: up, down or unchanged? 51
Commentary: associations between immune activation, intestinal permeability and irritable bowel syndrome 51
Enhanced platelet adhesion induces angiogenesis in the IBD microcirculation 51
Impact of Medications on Radiologic Disease Activity and Bowel Damage in Crohn's Disease: A Prospective Longitudinal MRI Study 51
When can unfractionated heparin really be useful in the treatment of ulcerative colitis? 51
The urokinase plasminogen activator receptor (uPAR) controls macrophage phagocytosis in intestinal inflammation 51
Stopping infliximab in crohn's disease: Still an ongoing STORI 51
Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsis 51
Quality of Care in Ulcerative Colitis: A Modified Delphi Panel Approach 51
Biological therapies for inflammatory bowel disease: Research drives clinics 50
Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease 50
Emerging therapeutic targets and strategies in Crohn's disease 50
High prevalence of infection by H. pylori cytotoxic type I strains in recurrent spontaneous abortion 50
Roseburia hominis: a novel guilty player in ulcerative colitis pathogenesis? 50
Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses 50
Microscopic features of colorectal neoplasia in inflammatory bowel diseases 50
The nocebo effect: a clinical challenge in the era of biosimilars 50
The CD40/CD40L costimulatory pathway in inflammatory bowel disease 50
5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial 50
Editorial: long-term safety and efficacy of certolizumab pegol for Crohn's disease 50
Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) 50
Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease 50
Clinical development of biologicals and biosimilars - safety concerns 50
Anti-IL-6 Treatment for Inflammatory Bowel Diseases: Next Cytokine, Next Target 50
Accuracy of Diffusion-weighted Magnetic Resonance Imaging in Detecting Mucosal Healing and Treatment Response, and in Predicting Surgery, in Crohn's Disease 50
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations 49
Anti-TNF biosimilars in Crohn's Disease: a patient-centric interdisciplinary approach 49
Risk of postoperative recurrence and postoperative management of Crohn's disease 49
Vascular involvement in inflammatory bowel disease: Pathogenesis and clinical aspects 49
Endoscopic mucosal resection for early colorectal neoplasia: pathologic basis, procedures, and outcomes. 49
Commentary: adjunct antibiotic combination therapy for ulcerative colitis - is it time to investigate Fusobacterium varium? 49
Preventing disability in inflammatory bowel disease 49
Totale 5.884
Salva come PNG Salva come JPEG
Categoria #
all - tutte 193.844
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 193.844
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202094 0 0 0 0 0 0 0 0 0 0 2 92
2020/20217.428 40 114 49 76 36 2.221 1.007 529 1.484 982 25 865
2021/20224.321 216 55 132 871 39 48 127 555 391 708 944 235
2022/202310.520 1.606 443 1.059 1.208 899 954 32 942 1.829 866 553 129
2023/20243.829 439 531 1.151 220 179 616 231 277 98 87 0 0
Totale 26.192